Literature DB >> 12880593

Immunological and pathological evaluation of rhesus macaques infected with Leishmania major.

Brenda L Freidag1, Susana Mendez, Allen W Cheever, Richard T Kenney, Barbara Flynn, David L Sacks, Robert A Seder.   

Abstract

Cutaneous leishmaniasis, a parasitic infection causing ulcerating skin lesions, is an important disease worldwide and urgently requires a vaccine. Animal models that closely mimic human disease are essential for designing preventive vaccines against Leishmania major. We have evaluated both biologic and immunologic parameters of cutaneous L. major infection in nonhuman primates. Naïve rhesus macaques or monkeys previously exposed to L. major were infected with varying doses of L. major metacyclic promastigotes, and lesion size was assessed over a 10-week period. Monkeys previously infected with L. major had much smaller lesions that resolved faster compared with those of naïve monkeys in response to the two higher doses of infection. Moreover, eight of nine naïve monkeys had parasites detected in their lesions during the course of the infection. In addition, the cellular infiltrate within the lesions was qualitatively and quantitatively different in naïve versus previously infected monkeys. Finally, an ELIspot assay determined that the magnitude and kinetics of responses differed between previously infected and naïve monkeys.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12880593     DOI: 10.1016/s0014-4894(03)00099-7

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  7 in total

1.  SIV infection of rhesus macaques results in dysfunctional T- and B-cell responses to neo and recall Leishmania major vaccination.

Authors:  Nichole R Klatt; Carol L Vinton; Rebecca M Lynch; Lauren A Canary; Jason Ho; Patricia A Darrah; Jacob D Estes; Robert A Seder; Susan L Moir; Jason M Brenchley
Journal:  Blood       Date:  2011-09-29       Impact factor: 22.113

2.  Immunity to visceral leishmaniasis using genetically defined live-attenuated parasites.

Authors:  Angamuthu Selvapandiyan; Ranadhir Dey; Sreenivas Gannavaram; Ines Lakhal-Naouar; Robert Duncan; Poonam Salotra; Hira L Nakhasi
Journal:  J Trop Med       Date:  2011-09-06

Review 3.  Of Drugs and Trypanosomatids: New Tools and Knowledge to Reduce Bottlenecks in Drug Discovery.

Authors:  Arijit Bhattacharya; Audrey Corbeil; Rubens L do Monte-Neto; Christopher Fernandez-Prada
Journal:  Genes (Basel)       Date:  2020-06-29       Impact factor: 4.096

Review 4.  Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis.

Authors:  Diana Caridha; Brian Vesely; Katrien van Bocxlaer; Byron Arana; Charles E Mowbray; Sima Rafati; Silvia Uliana; Rosa Reguera; Mara Kreishman-Deitrick; Richard Sciotti; Pierre Buffet; Simon L Croft
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2019-06-20       Impact factor: 4.077

5.  Non-human primates and Leishmania immunity.

Authors:  Sonia André; Vasco Rodrigues; Morgane Picard; Ricardo Silvestre; Jérôme Estaquier
Journal:  Cytokine X       Date:  2020-10-12

Review 6.  Role of Cytokines in Experimental and Human Visceral Leishmaniasis.

Authors:  Mukesh Samant; Utkarsha Sahu; Satish Chandra Pandey; Prashant Khare
Journal:  Front Cell Infect Microbiol       Date:  2021-02-18       Impact factor: 5.293

Review 7.  A Review: The Current In Vivo Models for the Discovery and Utility of New Anti-leishmanial Drugs Targeting Cutaneous Leishmaniasis.

Authors:  Emily Rose Mears; Farrokh Modabber; Robert Don; George E Johnson
Journal:  PLoS Negl Trop Dis       Date:  2015-09-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.